Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers

Jun 25 2019

• By Malcolm Spicer

Vintage inscription made by old typewriter, warning

Related Content

DEA Proposal To Schedule Kratom Stirs Wave Of Opposition

Dec 08 2016

Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI

Dec 15 2017

Kratom Advocates Urge Industry Compliance, FDA And DEA Compassion

Mar 08 2018

Wellness Industry News: GMP Complaint Against Confidence USA, Crown Labs Expands Again, More

May 24 2019

Health And Wellness News: FDA Enforcement Discretion On Allulose Labeling, More

Apr 18 2019

Kratom Industry Looks For States' Help; Heavy Metals Tests Tarnish Its Image

Apr 08 2019

Kratom Industry Group Has First Qualifier For Its GMP Standards Exceeding FDA's

Mar 13 2019

FDA's Opioid Label For Kratom Called Misbranding By Marketers

Feb 07 2018

Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

Jan 25 2018

Additional Topics

United States US States Advertising, Marketing & Sales Commercial Compliance Distribution Enforcement Ingredients Manufacturing Policy Regulation Safety Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window